SCHEMBL3577243

SCHEMBL3577243

Cc1ccc(NC(=O)NCc2ccccc2N2CCOCC2)cc1C#Cc1cnc(NCCN2CCOCC2)nc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 5/20 0.45
MAPK14 Q16539 3/20 0.45
KIT P10721 2/20 0.42
RIPK1 Q13546 1/20 0.41
RIPK3 Q9Y572 1/20 0.41
KDR P35968 3/20 0.39
FGFR1 P11362 1/20 0.39
BRD4 O60885 1/20 0.39
BRD9 Q9H8M2 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
SRC P12931 1/20 0.38
TYK2 P29597 1/20 0.38
SYK P43405 1/20 0.38
MAPK8 P45983 1/20 0.38
MAPK9 P45984 1/20 0.38
JAK3 P52333 1/20 0.38
MAPK10 P53779 1/20 0.38
BTK Q06187 1/20 0.38
ABL1 P00519 1/20 0.38
CYP3A4 P08684 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13500276 0.87 RIPK1 (0.50) LCKMAPK14KITRIPK1RIPK3
SCHEMBL3574150 0.82 SMN1; SMN2 (0.45) LCKMAPK14RIPK1RIPK3FGFR1
SCHEMBL3587191 0.81 CSNK2A1 (0.41) LCKMAPK14SMN1; SMN2EPHX2
SCHEMBL3581924 0.81 CNR2 (0.43) LCKMAPK14KDRSMN1; SMN2ABL1
SCHEMBL3663799 0.81 LCK (0.40) LCKMAPK14RIPK1RIPK3KDR
SCHEMBL3579024 0.80 LCK (0.48) LCKMAPK14KITRIPK1RIPK3
SCHEMBL4639353 0.80 MAPK14 (0.58) LCKMAPK14KITRIPK1RIPK3
SCHEMBL3584955 0.79 GAA (0.41) LCKBRD4BRD9CYP3A4MAPT
SCHEMBL3579827 0.78 AURKA (0.43) LCKMAPK14RIPK1RIPK3JAK3
SCHEMBL5276497 0.77 SMN1; SMN2 (0.48) SMN1; SMN2MAPK8CYP3A4CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY ASTRAZENECA AB (SE) 2010-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048543-A1 PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY TEK, TYMP, TIE1 LCK 326/4885MAPK14 1894/4885KIT 27/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.